AMINOPYRIMIDINYLAMINOBENZONITRILE DERIVATIVES AS NEK2 INHIBITORS
The present invention provides aminopyrimidinylaminobenzonitrile compounds that inhibit the activity of never in mitosis gene A-related kinase 2 (NEK2) and are useful in the treatment of diseases related to activity of NEK2, including cancer (e.g., multiple myeloma, and breast, liver, pancreatic and colorectal cancers).
1 . A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is H or alkyl;
R 2 is alkoxy, alkyl, cycloalkyl, halo or —OH;
R 3 is methoxy, H or fluoro, and when R 3 is H or fluoro, n is 0 or 1, and when R 3 is methoxy, n is 0; and
Cy is a moiety having the structure:
wherein:
A and B are independently selected from CH or N, with the proviso that when one of A or B is N the other is CH;
X is a bond, CH 2 , or C(O);
R 4 is alkoxy or halo;
p is 0, 1 or 2;
Y is N or CH;
Z is NH, N(CH 2 ) 0-2 CH 3 , N—(CH 2 ) 1-3 N(CH 3 ) 2 N(CH 2 ) 1-2 OH or O; and
R 5 is
or —(CH 2 ) 1-3 N(CH 3 ) 2 .
2 . The compound of claim 1 , wherein R 1 is H or methyl.
3 . The compound of claim 2 , wherein R 1 is H.
4 . The compound of claim 3 , wherein R 1 is methyl.
5 . The compound of any one of claims 1 - 4 , R 2 is methoxy, OH, chloro, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl.
6 . The compound of claim 5 , wherein R 2 is chloro.
7 . The compound of any one of claims 1 - 6 , wherein R 3 is fluoro.
8 . The compound of any one of claims 1 - 6 , wherein R 3 is H and n is 1.
9 . The compound of any one of claims 1 - 8 , wherein Cy is:
10 . The compound of any one of claims 1 - 9 , wherein A and B are each CH.
11 . The compound of any one of claims 1 - 10 , wherein R 4 is methoxy or fluoro.
12 . The compound of any one of claims 1 - 11 , wherein p is 0 or 1.
13 . The compound of claim 12 , wherein p is 0.
14 . The compound of any one of claims 1 - 13 , wherein X is a bond.
15 . The compound of any one of claims 1 - 14 , wherein Y is N.
16 . The compound of any one of claims 1 - 15 , wherein Z is NH, NCH 3 or O.
17 . The compound of claim 16 , wherein Z is NH.
18 . The compound of claim 16 , wherein Z is NCH 3 .
19 . The compound of claim 16 , wherein Z is O.
20 . The compound of any one of claims 1 - 15 , wherein Z is NCH 2 CH 2 OH.
21 . The compound of any one of claims 1 and 10 - 20 , wherein R 1 is H; R 2 is chloro; R 3 is fluoro and Cy is:
22 . The compound of any one of claims 1 - 21 , having the structure of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
R 4A and R 4B are each independently selected from H, methoxy or fluoro.
23 . The compound of any one of claims 1 - 8 , having the structure of Formula III:
or a pharmaceutically acceptable salt thereof.
24 . The compound of any one of claims 1 - 8 and 23 , wherein R 5 is CH 2 CH 2 N(CH 3 ) 2 .
25 . A compound of claim 1 , selected from:
or a pharmaceutically acceptable salt of any of the foregoing.
26 . A compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
27 . A compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
28 . A compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
29 . A compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
30 . A compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
31 . A compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
32 . A compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
33 . A compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
34 . A compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
35 . A composition comprising at least one compound of any one of claims 1 - 34 , or at least one compound thereof in the form of a pharmaceutically acceptable salt, and at least one pharmaceutically acceptable excipient.
36 . A method of inhibiting the activity of NEK2 in a subject having a condition in which NEK2 has activity above normally functioning cells, comprising administering to the subject at least one compound of any one of claims 1 - 34 , or at least one compound thereof in the form of a pharmaceutically acceptable salt, in an amount sufficient to reduce the level of NEK2 activity.
37 . A method of treating a disease in a subject, wherein the disease is associated with NEK2 activity, comprising administering to the subject a therapeutically effective amount of at least one compound of any one of claims 1 - 34 , or at least one compound thereof in the form of a pharmaceutically acceptable salt.
38 . The method of claim 37 , wherein the disease is cancer.
39 . A method of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of at least one compound of any one of claims 1 - 34 , or at least one compound thereof in the form of a pharmaceutically acceptable salt.
40 . The method of claim 38 or 39 , wherein the cancer is a solid tumor cancer.
41 . The method of claim 40 , wherein the cancer is a tumor of the bones, digestive organs, reproductive organs, head, neck, lung, heart, skin, nervous system, endocrine system, neuroendocrine system, urinary system, soft tissue, or brain, melanoma, renal cell cancer, non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), cervical cancer, ovarian cancer, melanoma, breast carcinoma, neuroendocrine carcinoma, prostate cancer, cholangiocarcinoma, uterine carcinoma, neuroblastoma, peripheral nerve sheath tumor, testicular cancer, bladder cancer, pancreatic cancer and pancreatic cancer.
42 . The method of claim 38 or 39 , wherein the cancer is a hematologic cancer.
43 . The method of claim 42 , wherein the hematologic cancer is multiple myeloma, myelodysplastic syndrome (MDS), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), acute lymphocytic leukemia, chronic lymphogenous leukemia, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, or non-Hodgkin's lymphoma.
44 . The method of claim 38 or 39 , wherein the cancer is breast cancer.
45 . The method of claim 38 or 39 , wherein the cancer is liver cancer.
46 . The method of claim 45 , wherein the liver cancer is hepatocellular carcinoma (HCC).
47 . The method of claim 38 or 39 , wherein the cancer is pancreatic cancer.
48 . The method of claim 47 , wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.
49 . The method of claim 38 or 39 , wherein the cancer is colorectal cancer.
50 . The method of claim 38 or 39 , wherein the cancer is non-small cell lung cancer (NSCLC) or lung adenocarcinoma.
51 . The method of claim 38 or 39 , wherein the cancer is mantle cell lymphoma or diffuse large B-cell lymphoma.
52 . The method of any one of claims 37 - 51 , further comprising administering to the subject one or more additional pharmaceutical agents.
53 . A combination comprising at least one compound of any one of claims 1 - 34 , or at least one compound thereof in the form of a pharmaceutically acceptable salt, and one or more additional pharmaceutical agents.
54 . A method of inhibiting EZH2 expression or activity in a subject, comprising administering to the subject at least one compound of any one of claims 1 - 34 , or at least one compound thereof in the form of a pharmaceutically acceptable salt, in an amount sufficient to reduce the expression or activity of EZH2.
55 . The method of claim 54 , wherein the expression or activity of EZH2 is reduced without disrupting cell cycle progression.
56 . The method of any one of claims 36 - 52 , 54 and 55 , further comprising measuring expression or activity of EZH2 in the subject.
57 . The method of any one of claims 36 - 52 , 54 and 55 , further comprising measuring expression or activity of EZH2 in the subject, thereby determining efficacy of the compound, or pharmaceutically acceptable salt thereof, in the subject.